Avid nets financing

Molecular imaging developer Avid Radiopharmaceuticals has closed a $26 million series C financing, co-led by AllianceBernstein and Safeguard Scientifics.

The financing positions Avid to advance its pipeline of diagnostic molecular imaging compounds for neurological disorders, including Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies (DLB), according to the Philadelphia-based firm.

By AuntMinnie.com staff writers
May 10, 2007

Related Reading

Avid releases results for PET Alzheimer's agent, March 23, 2007

Schering, Avid partner on Alzheimer's agents, July 17, 2007

Avid gets funding for new radiotracer, January 25, 2005

Copyright © 2007 AuntMinnie.com

Page 1 of 593
Next Page